- Reuters, Monday, May 8, 2023 3:55 PM
Eli Lilly is aiming for fast-track approval of one of its diabetes drugs for use in an even bigger secondary market: to treat obesity. "Cutting just several months
off the approval process could yield $30 billion in additional value," per Reuters. "The success doesn't, however, speak to the effectiveness of the government program used to get there."Read the whole story at Reuters »
